INCYTE CORPORATION Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
INCYTE CORPORATION (INCY) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $126.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-10
- INCYTE CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2016-12-31 was $286.90M.
- INCYTE CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $126.50M, a 191.47% increase from fiscal 2024.
- INCYTE CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $43.40M, a 97.29% decline from fiscal 2023.
- INCYTE CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $1.60B, a 2403.91% increase from fiscal 2022.
- INCYTE CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $63.90M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|
| 2025-12-31 | $126.50M 10-K · filed 2026-02-10 | ||
| 2024-12-31 | $43.40M 10-K · filed 2026-02-10 | ||
| 2023-12-31 | $1.60B 10-K · filed 2025-02-10 | ||
| 2022-12-31 | $63.90M 10-K · filed 2024-02-13 | ||
| 2021-12-31 | -$522.00M 10-K · filed 2023-02-07 | ||
| 2020-12-31 | $159.70M 10-K · filed 2022-02-08 | ||
| 2019-12-31 | -$66.50M 10-K · filed 2022-02-08 | ||
| 2018-12-31 | $2.20M 10-K · filed 2021-02-09 | ||
| 2017-12-31 | $14.60M 10-K · filed 2020-02-13 | ||
| 2016-12-31 | $286.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $277.30M 10-K · filed 2019-02-14 | |
| 2016-09-30 | -$9.60M 10-Q · filed 2016-11-01 | ||
| 2015-12-31 | -$126.20M 10-K · filed 2018-02-15 | ||
| 2014-12-31 | $42.20M 10-K · filed 2017-02-14 | ||
| 2013-12-31 | -$50.00M 10-K · filed 2016-02-12 | ||
| 2012-12-31 | -$16.00M 10-K · filed 2015-02-17 | ||
| 2011-12-31 | $72.00M 10-K · filed 2014-02-21 | ||
| 2010-12-31 | $11.00M 10-K · filed 2013-02-21 | ||
| 2009-12-31 | $68.00M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |